712515
O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol
Mw 3000
Synonym(s):
Polyethylene glycol, α-Mercapto-ω-carboxy-PEG
About This Item
Recommended Products
![O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol Mw 5000](/deepweb/assets/sigmaaldrich/product/structures/271/277/d02536f0-83d7-4416-9cea-f6213e09fe85/640/d02536f0-83d7-4416-9cea-f6213e09fe85.png)
![(R)-1-{(RP)-2-[2-(Diphenylphosphino)phenyl]ferrocenyl}ethylbis[3,5-bis-(trifluoromethyl)phenyl]phosphine ≥97%](/deepweb/assets/sigmaaldrich/product/structures/185/002/97358faf-b2d8-4de5-9315-73b6a8b3ae26/640/97358faf-b2d8-4de5-9315-73b6a8b3ae26.png)
![O-[2-(3-Mercaptopropionylamino)ethyl]-O′-methylpolyethylene glycol 5,000](/deepweb/assets/sigmaaldrich/product/structures/293/792/95ae9557-6907-4575-8903-f5b87ada86e2/640/95ae9557-6907-4575-8903-f5b87ada86e2.png)
form
powder
Quality Level
mol wt
Mw 3000
reaction suitability
reagent type: cross-linking reagent
Ω-end
thiol
α-end
carboxylic acid
storage temp.
−20°C
Looking for similar products? Visit Product Comparison Guide
Packaging
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Articles
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Protocols
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service